skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma

Abstract

Irisin is a newly identified myokine that may be cancer-associated, and its impact on liver cancer is unclear. To understand the roles of irisin in liver cancer, we investigated its effect in HepG2 and SMCC7721 hepatocellular carcinoma cells, and the underlying mechanisms. We determined irisin levels in liver tissues and serum samples obtained from patients by using real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Irisin levels in cancerous livers were significantly upregulated compared with those in control livers, but serum irisin levels remained unchanged. Additionally, we evaluated the effects of different concentrations of human recombinant modified and active (glycosylated) irisin (IM) or human recombinant nonmodified irisin (INM) on cell migration, proliferation, viability, and invasiveness. CCK8, transwell, and scratching assays demonstrated that irisin significantly increased cell proliferation, invasion, and migration through activation of the PI3K/AKT pathway. Irisin-induced cell proliferation, migration, and invasion were blocked by a PI3K inhibitor (LY294002). Irisin also decreased the cytotoxicity of doxorubicin in HepG2 cells. These data indicate that increased irisin levels may have protective roles in liver cancer cells through partial activation of the PI3K/AKT pathway, which may facilitate liver cancer progression and decrease the sensitivity to chemotherapy. - Highlights: • Irisin levels are upgradedmore » in patients with hepatocellular carcinoma. • Irisin induces cell proliferation, migration, invasiveness, and inhibit appotosis of cell induced by Dox. • Irisin induces the activation of PI3K/AKT pathway. • Irisin has protective roles in liver cancer cells, inducing disease progression.« less

Authors:
;  [1];  [2]; ;  [1]; ; ;  [3];  [3];  [1]
  1. Department of Hepatobiliary Surgery, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao 266000 (China)
  2. Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000 (China)
  3. Department of Gynecology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao China (China)
Publication Date:
OSTI Identifier:
22719130
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 493; Journal Issue: 1; Other Information: Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; CELL PROLIFERATION; CHAIN REACTIONS; CHEMOTHERAPY; DOXORUBICIN; HEPATOMAS; INTERNATIONAL MAGNETOSPHERIC STUDY; LIVER; PATIENTS; POLYMERASE CHAIN REACTION; POLYMERASES; SENSITIVITY; TOXICITY

Citation Formats

Shi, Guangjun, Tang, Nan, Qiu, Jiantao, Zhang, Deguo, Huang, Fei, Cheng, Yayu, Ding, Kun, Li, Weisheng, Zhang, Ping, and Tan, Xueying. Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. United States: N. p., 2017. Web. doi:10.1016/J.BBRC.2017.08.148.
Shi, Guangjun, Tang, Nan, Qiu, Jiantao, Zhang, Deguo, Huang, Fei, Cheng, Yayu, Ding, Kun, Li, Weisheng, Zhang, Ping, & Tan, Xueying. Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. United States. doi:10.1016/J.BBRC.2017.08.148.
Shi, Guangjun, Tang, Nan, Qiu, Jiantao, Zhang, Deguo, Huang, Fei, Cheng, Yayu, Ding, Kun, Li, Weisheng, Zhang, Ping, and Tan, Xueying. Sat . "Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma". United States. doi:10.1016/J.BBRC.2017.08.148.
@article{osti_22719130,
title = {Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma},
author = {Shi, Guangjun and Tang, Nan and Qiu, Jiantao and Zhang, Deguo and Huang, Fei and Cheng, Yayu and Ding, Kun and Li, Weisheng and Zhang, Ping and Tan, Xueying},
abstractNote = {Irisin is a newly identified myokine that may be cancer-associated, and its impact on liver cancer is unclear. To understand the roles of irisin in liver cancer, we investigated its effect in HepG2 and SMCC7721 hepatocellular carcinoma cells, and the underlying mechanisms. We determined irisin levels in liver tissues and serum samples obtained from patients by using real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Irisin levels in cancerous livers were significantly upregulated compared with those in control livers, but serum irisin levels remained unchanged. Additionally, we evaluated the effects of different concentrations of human recombinant modified and active (glycosylated) irisin (IM) or human recombinant nonmodified irisin (INM) on cell migration, proliferation, viability, and invasiveness. CCK8, transwell, and scratching assays demonstrated that irisin significantly increased cell proliferation, invasion, and migration through activation of the PI3K/AKT pathway. Irisin-induced cell proliferation, migration, and invasion were blocked by a PI3K inhibitor (LY294002). Irisin also decreased the cytotoxicity of doxorubicin in HepG2 cells. These data indicate that increased irisin levels may have protective roles in liver cancer cells through partial activation of the PI3K/AKT pathway, which may facilitate liver cancer progression and decrease the sensitivity to chemotherapy. - Highlights: • Irisin levels are upgraded in patients with hepatocellular carcinoma. • Irisin induces cell proliferation, migration, invasiveness, and inhibit appotosis of cell induced by Dox. • Irisin induces the activation of PI3K/AKT pathway. • Irisin has protective roles in liver cancer cells, inducing disease progression.},
doi = {10.1016/J.BBRC.2017.08.148},
journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 1,
volume = 493,
place = {United States},
year = {2017},
month = {11}
}